BOGOTA, Colombia, April 28, 2026 /PRNewswire/ -- Ecopetrol S.A ((BVC: ECOPETROL, NYSE:EC) hereby announces that on Tuesday, May 12, 2026, it will release its financial and operational results for the first quarter of 2026, after market closes. On Wednesday, May 13, 2026, the company's management will hold a virtual earnings conference call, with simultaneous webcasts in Spanish and English, at the following times:Conference Call 09:00 a.m. Colombia Time10:00 a.m. New York TimeTo participate in the conference call, please use the following link and select the preferred language f
Live Feed
Delayed 3mPress · Buys · SEC · FDA · Financials
Signed out · 3-min delay · Sign up for real-time
- Ecopetrol announces the dates for the release of its first quarter 2026 earnings report and conference call
- Pershing Square Announces Pricing of the Combined IPO of Pershing Square USA and Pershing Square Inc.
Aggregate offering size of $5 billion Pershing Square USA, Ltd. ("PSUS"), an investment company managed by Pershing Square Capital Management, L.P. ("PSCM"), and Pershing Square Inc. ("PSI"), the parent company of PSCM, today announced the pricing of the combined initial public offering (the "PSUS IPO") of the common shares of beneficial interest of PSUS (the "PSUS Shares") and the initial public offering (the "PSI IPO", and together with the PSUS IPO, the "Combined IPO") of the common stock of PSI (the "PSI Shares"). The PSUS Shares and the PSI Shares are expected to begin trading on the New York Stock Exchange (NYSE) on April 29, 2026, under the symbol "PSUS" for the PSUS Shares and u
- SEC Form SCHEDULE 13G filed by BRP Inc. Common Subordinate Voting Shares
SCHEDULE 13G - BRP Inc. (0001748797) (Subject)
- Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (NASDAQ:ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced the pricing of its upsized underwritten public offering of 9,660,000 shares of its common stock at a price to the public of $72.50 per share. The gross proceeds to Oruka from this offering are expected to be approximately $700.4 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. In additio
- Black Hills Corp. Announces Quarterly Dividend
RAPID CITY, S.D., April 28, 2026 (GLOBE NEWSWIRE) -- Black Hills Corp. (NYSE:BKH) today announced that its board of directors declared a quarterly dividend on the common stock at a meeting held April 28, 2026. Common shareholders of record at the close of business on May 15, 2026, will receive $0.703 per share, payable June 1, 2026. The company also confirms that it will release its 2026 first-quarter earnings after the market closes Wednesday, May 6, 2026, and will host a live conference call and webcast at 11 a.m. EDT on Thursday, May 7, 2026, to discuss the company's financial results. To participate by phone and ask a question during the live broadcast, participants can access the ev
- Trimble Links SketchUp with Anthropic's Claude, Bringing New Conversational AI-powered Capabilities to 3D Modeling
Trusted, intuitive AI enhances design workflows, making it easier to move from creative concepts to 3D modelsWESTMINSTER, Colo., April 28, 2026 /PRNewswire/ -- Trimble (NASDAQ:TRMB) today announced a specialized integration with Claude, the large language model and AI assistant from Anthropic, that makes it easier for Trimble® SketchUp® software users to create 3D models directly from conversational text or speech prompts. The powerful new capabilities are enabled by a SketchUp Connector model context protocol (MCP) service that allows Claude to interact directly with SketchUp (
- Borealis Foods Announces $17.0 Million Refinancing Transaction with Oxus Capital to Repay Frontwell Facility and Support Operations
TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Borealis Foods Inc. (NASDAQ:BRLS) ("Borealis" or the "Company"), a food science company focused on nutritious, convenient food solutions, today announced that its subsidiaries entered into a $17.0 million term loan facility with Oxus Capital PTE Ltd. ("Oxus"), a significant shareholder of the Company, to repay in full the Company's existing obligations to Frontwell Capital Partners Inc. ("Frontwell"), improve near-term financial flexibility, and support operations. The transaction reflects confidence in Borealis' operating platform and market opportunity. The Company continues to see demand for its flagship products, including Chef Woo, Ramen Ex
- FirstCash Announces Upsize and Pricing of $750 Million Senior Notes Due 2034
FORT WORTH, Texas, April 28, 2026 (GLOBE NEWSWIRE) -- FirstCash Holdings, Inc. ("FirstCash" or the "Company") (NASDAQ:FCFS) today announced that the Company's wholly-owned subsidiary, FirstCash, Inc. (the "Issuer"), has upsized and priced its previously announced private offering of $750,000,000 in aggregate principal amount of senior notes due 2034 (the "Notes"), representing an increase of $150,000,000 in aggregate principal amount from the previously announced proposed offering size. The Notes will pay interest semi-annually at a rate of 6.125% per annum payable on May 1 and November 1 of each year, beginning on November 1, 2026. The Notes will be unsecured senior obligations of the Is
- Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in New England Journal of Medicine (NEJM) Evidence1. The findings of this pivotal phase III study are included in the Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), submitted to the U.S. Food and Drug Administration (FDA) with a target action date of December 12, 2026.ReferencesSmiesz
- /C O R R E C T I O N -- Elanco Animal Health/
/C O R R E C T I O N – Elanco Animal Health/ In the news release, Elanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock, issued 27-Apr-2026 by Elanco Animal Health over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Elanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock Action Prepares Veterinarians and Livestock Prod
- Amendment: SEC Form SCHEDULE 13G/A filed by Select Water Solutions Inc.
SCHEDULE 13G/A - Select Water Solutions, Inc. (0001693256) (Subject)
- Amendment: SEC Form SCHEDULE 13G/A filed by Ryerson Holding Corporation
SCHEDULE 13G/A - Ryerson Holding Corp (0001481582) (Subject)
- Amendment: SEC Form SCHEDULE 13G/A filed by Natural Gas Services Group Inc.
SCHEDULE 13G/A - NATURAL GAS SERVICES GROUP INC (0001084991) (Subject)
- Timberland Bancorp Reports Second Fiscal Quarter Net Income of $7.1 Million
EPS Increases 6% to $0.90 from $0.85 for the Comparable Quarter One Year AgoQuarterly Return on Average Assets of 1.43%Quarterly Return on Average Equity of 10.72%Quarterly Net Interest Margin of 3.81% HOQUIAM, Wash., April 28, 2026 (GLOBE NEWSWIRE) -- Timberland Bancorp, Inc. (NASDAQ:TSBK) ("Timberland" or "the Company"), the holding company for Timberland Bank (the "Bank"), today reported net income of $7.13 million, or $0.90 per diluted common share for the quarter ended March 31, 2026. This compares to net income of $6.76 million, or $0.85 per diluted common share for the comparable quarter one year ago, and $8.22 million, or $1.04 per diluted common share, for the preceding quarter.
- SEC Form SCHEDULE 13G filed by Cantor Equity Partners VI Inc.
SCHEDULE 13G - Cantor Equity Partners VI, Inc. (0002089536) (Subject)
- SEC Form SCHEDULE 13G filed by Surf Air Mobility Inc.
SCHEDULE 13G - SURF AIR MOBILITY INC. (0001936224) (Subject)
- SEC Form SCHEDULE 13G filed by Sidus Space Inc.
SCHEDULE 13G - Sidus Space Inc. (0001879726) (Subject)
- SEC Form 144 filed by Vitesse Energy Inc.
144 - Vitesse Energy, Inc. (0001944558) (Subject)